Valentina Oliveriab,
Francesco Belliac,
Giuseppa Ida Grassoc,
Adriana Pietropaolod and
Graziella Vecchio*a
aDipartimento di Scienze Chimiche, Università di Catania, Viale A. Doria 6, 95125, Catania, Italy. E-mail: gr.vecchio@unict.it
bConsorzio Interuniversitario di Ricerca in Chimica dei Metalli nei Sistemi Biologici C.I.R.C.M.S.B, Unità di Ricerca di Catania, 95125 Catania, Italy
cIstituto di Biostrutture e Bioimmagini, CNR, Via P. Gaifami 18, 95126 Catania, Italy
dDipartimento di Scienze della Salute, Università di Catanzaro, Viale Europa, 88100 Catanzaro, Italy
First published on 5th May 2016
Trehalose has been proven to provide protection to different proteins to various extents, inhibiting at elevated concentrations the aggregation of proteins involved in neurodegenerative disorders such Alzheimer's, Parkinson's and Huntington's diseases. Moreover, 8-hydroxyquinolines have also been found to protect against neurodegeneration in animal models. Here, we evaluated trehalose-8-hydroxyquinoline conjugates as antioxidants and inhibitors of self-induced Aβ aggregation. All trehalose derivatives demonstrate a significant in vitro antioxidant capacity and antiaggregant ability. The conjugation of trehalose with 8-hydroxyquinoline induces synergistic effects that lead to superior antiaggregant properties. In particular, 6,6′-difunctionalized trehalose is more effective than the corresponding 6-monofunctionalized compound suggesting that grafting two 8-hydroxyquinoline moieties on the disaccharide scaffold produces a better-performing antiaggregant compound. In silico data shed light on the binding modes of the 6-monofunctionalized and 6,6′-difunctionalized trehalose with Aβ. In particular, different to the 6-monofunctionalized compound, which mostly induces ring–ring or salt-bridge interactions also involving the glucose ring of trehalose, the 6,6′-difunctionalized derivative induces pi-stacking interactions involving 8-hydroxyquinoline moieties and the aromatic rings of F4, H14 and F20 of Aβ. The obtained results are encouraging and highlight the potential of trehalose derivatives as therapeutics for amyloid-related pathologies.
For this reason, multitarget-directed molecules have recently been proposed as agents more adequate for addressing the complexity of AD.4 Preventing or reducing Aβ aggregation is one of therapeutic strategies under development or in clinical trials for the treatment of AD. Preventing Aβ aggregation can be accomplished using a variety of inhibitors such as small organic molecules, including curcumin,5 8-hydroxyquinolines (OHQs),6 but also carbohydrates such as cyclodextrins7 (CyD) and trehalose (Tre) have been shown to stabilize protein folding and inhibit protein aggregation.
Tre (α-D-glucopyranosyl-(1,1)-α-D-glucopyranoside or trehalose) is a non-reducing disaccharide that generally exists in yeast, bacteria, fungi and invertebrates. This disaccharide is known to impart stability to organisms tolerating environmental stress such as anhydrobiosis and cryobiosis by protecting proteins and cells.8 Recent studies suggest that Tre can attenuate the insulin amyloid formation in vitro9 and aggregation of Aβ and tau, associated with AD pathology.10–12 Furthermore, Tre is also effective in inhibiting polyglutamine mediated protein aggregation and fibrillation of α-synuclein and alleviating the symptoms in models of HD13 and PD.14 Because of Tre is a relevant biological molecule in several species, considerable efforts have been invested in the design of Tre analogs, mimetics and derivatives as potential fungicides and antibiotics (especially for M. Tubercolosis).15 In some cases, 6,6′-difunctionalized derivatives are biologically more active than mono-substituted compounds and show interesting biological effects.16 To quote an example, a 6,6′-difunctionalized derivative known as Brartemicin, recently isolated from the actinomycete of the genus Nonomuraea inhibits cancer cell invasion.17,18
This context has inspired us to synthesize and analyze a new difunctionalized trehalose-8-hydroxyquinoline conjugate in depth. 8-Hydroxyquinolines have the capability to directly influence the self-association and in vivo toxicity of Aβ.19 These properties are complementary to the other mechanisms of action, described for two known OHQ derivatives (clioquinol and PBT2), associated with a ionophoric activity resulting in promotion of intracellular metal uptake by neurons.20
We have previously functionalized OHQs with sugars to ameliorate their properties. These glycoconjugates have interesting features including the enhancement of solubility, reduced toxicity, and multifunctionality.21–24 In particular, we have studied the metal-binding properties and the ability to inhibit metal-induced aggregation of Aβ and β-lactoglobulin A.25,26
Herein, we report the synthesis and characterization of 6,6′-dideoxy-6,6′-di[[(8-hydroxyquinoline)-2-carboxyl]amino]-α,α′-trehalose (Tre(HQ)2, Fig. 1). Moreover, we tested the ability of the new compound Tre(HQ)2, the analogous monosubstituted 6-deoxy-6-[[(8-hydroxyquinoline)-2-carboxyl]-amino]-α,α′-trehalose26 (TreHQ, Fig. 1) and 6-deoxy-6-[[(8-hydroxyquinoline)-2-methyl-amino]-α,α′-trehalose26 (TreRHQ, Fig. 1) to scavenge free radical species and inhibit Aβ aggregation. We also tested a bis(8-hydroxyquinoline) compound (HQ)2, 8-hydroxyquinolinecarboxamide (HQ) and Tre to examine the role of the sugar and/or quinoline moieties in inhibiting free radical species and protein aggregation.
Fig. 1 Chemical structure of the investigated compounds: trehalose-8-hydroxyquinoline conjugates and their parent compounds (HQ and Tre). |
The activity of the Tre-HQ derivatives toward Aβ, and radical species confirms that the conjugation of Tre with one or more HQ moieties represents a promising strategy to design new molecules that target and modulate pathological features of neurodegenerative disorders.
These findings may contribute to the understanding of the features that interfere with protein aggregation and, thus, these studies might address those seeking better inhibitors.
ESI-MS experiments provided evidence that the compound was difunctionalized because the spectra display the peaks resulting from the singly charged ions at m/z = 683.1 and 705.2 (assigned to [M + H]+ and [M + Na]+).
1H NMR spectrum of Tre(HQ)2 displays the signals due to the quinoline ring and Tre moiety, the former resonating in the aromatic region between 8.38 and 7.14 ppm (Fig. 2). 2D spectra allowed unambiguous assignment of all protons and carbons (Fig. S1 and S2†). Because of the symmetry of the molecule, the protons of the glucose rings as well as those of quinoline moieties are equivalent. The Hs-1 of Tre resonate at 5.08 ppm, Hs-6 and Hs-5 are shifted downfield at 3.75 and 4.08 ppm upon functionalization. As observed in the 13C NMR spectrum (Fig. S3†), C-1 carbons resonate at δ = 95.7 ppm and it is noteworthy that C-6 carbons are significantly shifted at 41.1 ppm owing to the derivatization. The UV-vis spectrum of Tre(HQ)2 in MOPS buffer (pH 7.4) is characterized by absorption bands at 253, 307, and 351 nm (Fig. S4†). The UV bands of this compound are assigned to the π–π* and n–π* transitions, similarly to other alike systems.27
The ability of Tre(HQ)2 to scavenge free radicals was determined by ABTS radical assay. Trolox, a water soluble vitamin E analogue, was used as a standard, and the results are expressed as Trolox Equivalent Antioxidant Capacity (TEAC). The antioxidant efficiency of the phenolic compounds is related to the number of hydroxyl groups in the molecule and also to other effects such as hydrogen atom donating ability of the compounds. The nature of substituent effects (electron-withdrawing, electron donator, inductive effects) has an influence on the H-donating ability of hydroxyl group. As a consequence, the functionalization of HQ moiety to append a sugar could influence the scavenging ability, increasing or reducing TEAC values as observed in the case of other derivatives.22 The TEAC values of Tre(HQ)2 are reported in Fig. 3. To obtain a more complete picture of the role of the HQ moiety and, in particular, of the phenolic group, TEAC values of the parent compounds HQ and (HQ)2 were also determined as well as those of TreHQ and TreRHQ were reported (Fig. 3). The results showed that phenolic groups play an important role in the antioxidant activity of the tested compounds. It is noteworthy that phenolic compounds exhibit a wide range of biological functions that are attributed to their radical-scavenging activity.
Fig. 3 TEAC values at 1, 3, and 6 min for Tre derivatives, HQ and (HQ)2. Means are the average of three independent trials, and error bars show standard deviations. |
All compounds are more active than Trolox and this higher activity is generally related to a good protective function against oxidative stress. Furthermore, the difunctionalized systems have better antioxidant activity than compounds with only one HQ moiety. Among all of the derivatives tested, Tre(HQ)2 showed the best antioxidant activity, which was close to that of (HQ)2. At the end point (after 6 min), Tre(HQ)2 showed a TEAC value of 2.9, which is higher than the reported value for gallic acid (2.6), a naturally occurring polyphenol antioxidant, which has recently been shown to have potential health effects. These data suggest that Tre(HQ)2 could be a powerful antioxidant with activity comparable to that of several polyphenols.
Fig. 4 Turbidimetric measurements of Aβ1–42 alone (CTRL) or with each tested compound (TreHQ, TreRHQ and Tre(HQ)2. The peptide-to-ligand molar ratio ([Aβ]/[L]) ranged to 1:1 to 1:10. |
Fmax − F0 (RFU) | K (h) | tlag (h) | Fmax − F0 (RFU) | K (h) | tlag (h) | |
---|---|---|---|---|---|---|
CTRL | ||||||
8.04 ± 0.06 | 1.84 ± 0.05 | 10.9 ± 0.3 | ||||
[Aβ]/[L] | TreHQ | TreRHQ | ||||
1/1 | 6.0 ± 0.1 | 1.2 ± 0.1 | 12.2 ± 0.2 | 6.09 ± 0.08 | 1.79 ± 0.09 | 14.8 ± 0.3 |
1/2 | 5.3 ± 0.1 | 1.31 ± 0.06 | 11.9 ± 0.2 | 6.06 ± 0.04 | 2.55 ± 0.06 | 25.2 ± 0.2 |
1/5 | 5.0 ± 0.1 | 1.9 ± 0.1 | 18.6 ± 0.4 | 4.64 ± 0.05 | 1.46 ± 0.06 | 23.3 ± 0.2 |
1/10 | 4.9 ± 0.3 | 2.50 ± 0.07 | 20.0 ± 0.2 | 3.48 ± 0.04 | 2.88 ± 0.08 | 28.4 ± 0.3 |
Tre(HQ)2 | (HQ)2 | |||||
1/1 | 7.7 ± 0.3 | 2.5 ± 0.5 | 11 ± 2 | 5.89 ± 0.04 | 2.24 ± 0.06 | 16.9 ± 0.4 |
1/2 | 5.1 ± 0.3 | 3.7 ± 0.5 | 12 ± 3 | 5.71 ± 0.06 | 2.18 ± 0.09 | 18.4 ± 0.1 |
1/5 | 3.6 ± 0.4 | 1.6 ± 0.9 | 14 ± 1 | 4.92 ± 0.08 | 2.12 ± 0.12 | 17.7 ± 0.4 |
1/10 | 1.9 ± 0.2 | 1.1 ± 0.5 | 16 ± 2 | 3.73 ± 0.07 | 1.60 ± 0.11 | 19.2 ± 0.2 |
Tre | ||||||
1/1 | 7.0 ± 0.2 | 3.6 ± 0.3 | 14 ± 2 | |||
1/2 | 6.4 ± 0.1 | 3.6 ± 0.2 | 16.0 ± 0.8 | |||
1/5 | 5.1 ± 0.2 | 2.7 ± 0.5 | 16 ± 1 | |||
1/10 | 4.7 ± 0.3 | 2.8 ± 0.4 | 20.8 ± 0.9 |
The characteristic amyloid aggregation of Aβ is witnessed by the sigmoid trend of the ThT fluorescence response.31 A lag phase of 12 h is also a reliable value on the basis of the experimental conditions that mainly influence it, namely buffer composition, ion strength, protein concentration and temperature. The level of amyloid-type aggregation is proportional to the total fluorescence gain (Fmax − F0); for this reason, whenever a compound is tested, the greater the discrepancy of the Fmax − F0 value to that reported for Aβ alone (8.04), the higher the anti- or pro-aggregant activity of that compound.
An overall look at the kinetic parameters (Table 1) shows that the dose-dependent investigation of TreHQ, Tre(HQ)2, TreRHQ and (HQ)2 gives common outcomes: Fmax − F0 increases as the concentration of the tested compound increases. The lag phase is lengthened upon increasing the compound concentration as well. The shared behavior towards the amyloid aggregation is a further proof of the well-known antiaggregant propriety of 8-hydroxyquinoline moiety.6
As for TreHQ, the extent of the peptide aggregation is significantly reduced when the Aβ/compound ratio is even 1:1.
TreHQ also delays the fibril formation, being the lag phase (12.2 h) increased with respect to that of the control sample (10.9 h). Doubling the concentration of this compound, there is only a slight effect on the maximum fluorescence variation (Fmax − F0), whereas the lag phase values definitely increase when TreHQ concentration is five- or ten-fold to that of the amyloid peptide.
TreRHQ also causes dose-dependent changes on the kinetic profiles of the amyloid aggregation (Fig. 5).
Fmax − F0 is almost halved and the lag time is nearly doubled at the highest Aβ-to-compound ratio tested compared to fitted kinetic parameters of the Aβ aggregation alone. For these reasons, TreRHQ behaves better than TreHQ as antiaggregant agent, decreasing extent of amyloid aggregation and delaying formation of ThT-responsive aggregates.
Assaying Tre(HQ)2 on the aggregation of Aβ1–42 means testing the effect of two HQ moieties covalently linked to a Tre unit. This glycoconjugate undoubtedly reduces the amount of amyloid aggregates (Fmax − F0 decreases) in a direct proportion to the amount of Tre(HQ)2. Moreover, such a result is better than those produced by TreHQ and TreRHQ. However, differently by the mono-functionalized derivatives, Tre(HQ)2 had a poor effect on the lag phase of the amyloid aggregation process.
The quinoline derivatives HQ and (HQ)2, Tre and mixtures of Tre and HQ were also tested with the aim of getting information on the role that Tre unit or OHQ moiety could have on the antiaggregant property of the derivatives. The outcome (Tables 1 and S1†) reveals that both Tre and HQ have antiaggregant activity, although they are less effective than the derivatives in inhibiting Aβ aggregation. (HQ)2 also promotes the decrease of the Fmax − F0 value in a dose dependent manner, although the value of this parameter (3.73) is higher than that obtained in the presence of Tre(HQ)2 (1.9) at the highest peptide-to-compound ratio tested (1:10).
This clearly means that Tre has an active role on the antiaggregant activity of Tre(HQ)2 in keeping with the activity of Tre that progressively reduced the aggregation extent (Fmax − F0) with the increase of the concentration. As for the mixtures of Tre and HQ, the effect of Tre(HQ)2 is comparable to that for a combination of Tre and HQ in 1:2 molar ratio, whereas TreHQ has an activity higher than that of a Tre_HQ combination (1:1 molar ratio). Anyway, the main advantage of the covalent conjugation of HQ and Tre to form TreHQ and Tre(HQ)2 is the enhanced water solubility with respect to HQ. Moreover, the potential physiological fate the covalent derivatives should be reasonably different to that of the simple combination of the parent compounds.
Overall, mono- and bis-HQ derivatives of Tre display antiaggregant activity towards the formation of Aβ-containing fibrils at micromolar concentrations. Both the quinoline and the Tre units play an important role on this pathologically significant pathway of Aβ1–42 and two HQ units linked to Tre exert a better effect on the inhibition process than that showed by the monofunctionalized TreHQ. In line with this trend, the difunctionalization of cyclodextrin with HQ was also more effective strategy to suppress the amyloid aggregation than the mono-derivatization one (Fig. 6).22 The IC50 value of Tre(HQ)2 (38.9 μM) makes this compound a potential candidate for treating AD.
The conformations of Aβ1–42 obtained from parallel tempering simulations highlight pliant domains, as also reported in previous contributions22,32,33 where short sections of alpha helix regions are stabilized along the backbone and all of them are connected through loop states.
Upon the binding of Tre(HQ) and Tre(HQ)2 to Aβ1–42, specific binding poses have been detected.
In particular, when Tre(HQ) is docked to Aβ1–42 three main binding poses with fairly close energy levels have been obtained. As similarly observed in the 8-hydroxyquinoline-appended cyclodextrin moiety docked to Aβ1–42,22 a first binding pose indicates a pi-stacking of the Y10 ring belonging to Aβ1–42 with the Tre(HQ) ligand, together with a ring–ring interactions between the α-glucose ring of the Tre and the aromatic ring of H14 (Fig. 7a), a non-covalent interaction observed in trehalose–histidine supramolecular frameworks.34 In the second binding pose the Tre(HQ) moiety lays among the intramolecular salt-bridges in the peptide scaffold of Aβ1–42 between the arginine group of R5 and the C-terminal carboxyl group of A42 (Fig. 7b). In the third binding poses, the Tre(HQ) ligand embraces the peptide scaffold of Aβ1–42 within the central loop region encompassing H14 and F20 residues (Fig. 7c).
The docking of Aβ1–42 with Tre(HQ)2 induces slightly different binding poses with fairly close energy levels. In particular, in the first binding pose the residues F4, H14 and F20 enclose the Tre(HQ)2 moiety, inducing a quite compact ligand-peptide supramolecular complex (Fig. 7d). In the second binding pose, F20 is stacked with one OHQ appended to the Tre ring (Fig. 7e), whereas in the third binding pose similarly to what found upon docking Tre(HQ) with the elongated cluster of Aβ1–42. Tre(HQ)2 lays in the central peptide loop encompassing the residues from H14 to F20 (Fig. 7f). The docking simulations provide a snapshot of molecular interactions to find out whether there is a direct interaction between Aβ and the compounds at atomic level. The results indicate that trehalose derivatives can bind to Aβ, suggesting a possible mechanism of interfering with the amyloid aggregation.
Computational studies indicate that the derivatives can interact with Aβ stabilizing the monomer and thus avoiding the aggregation pathway. These finding that Tre-HQ conjugates, especially the 6,6′-difunctionalized compound, can interact with Aβ interfering with its self-aggregation are encouraging and underscore the potential of trehalose derivatives as therapeutics for amyloid-related pathologies.
6-Deoxy-6-[[(8-hydroxyquinoline)-2-carboxyl]-amino]-α,α′-trehalose (TreHQ) and 6-deoxy-6-[[(8-hydroxyquinoline)-2-methyl-amino]-α,α′-trehalose were synthesized as reported elsewhere.26
Thin layer chromatography (TLC) was performed on silica gel plates (Merck 60-F254) detecting carbohydrate derivatives by UV and/or anisaldehyde test.
Yield: 75%. TLC: Rf = 0.45 (PrOH/AcOEt/H2O/NH3 5:3:1:2). (ESI-MS,+): m/z = 683.1 [M + H]+, 705.2 [M + Na]+. UV-vis (MOPS, pH 7.4): λ nm (ε M−1 cm−1) 253 (40100), 307 (3073), 351 (1913).
1H NMR (500 MHz, CD3OD) δ (ppm): 8.38 (d, 2H, J4,3 = 8.6 Hz, H-4), 8.16 (d, 2H, J3,4 = 8.6 Hz, H-3), 7.51 (t, 2H, J = 7.9 Hz, H-6), 7.41, (d, 2H, J5,6 = 7.7 Hz, H-5), 7.14 (dd, 2H, J7,6 = 7.5 Hz, J7,5 = 0.7 Hz, H-7), 5.08 (d, 2H, J1,2 = 3.8 Hz, Hs-1 of Tre), 4.08 (dt, 2H, J5,4 = 9.8 Hz, J5,6 = 4.9 Hz, Hs-5 of Tre), 3.81 (t, 2H, J = 9.3 Hz, Hs-3 of Tre), 3.75 (d, 4H, J6,5 = 4.9 Hz, Hs-6 of Tre), 3.46 (dd, 2H, J2,3 = 9.7 Hz, J2,1 = 3.8 Hz, Hs-2 of Tre), 3.22 (t, 2H, J = 9.3 Hz, Hs-4 of Tre).
13C NMR (125 MHz, CD3OD) δ (ppm): 167.3 (carbonyl Cs), 154.9 (Cs-8), 148.5 (Cs-2), 138.8 (Cs-4), 138.6 (Cs-9), 131.4 (Cs-10), 130.5 (Cs-6), 120.0 (Cs-5), 118.9 (Cs-3), 112.8 (Cs-7), 95.7 (Cs-1 of Tre), 74.3–72.2.2 (Cs-2, Cs-3, Cs-4 and Cs-5 of Tre), 41.1 (Cs-6 of Tre).
tlag = t1/2 − 2k |
The kinetic parameters of any set of measurements were expressed as mean ± SD. In addition, point-based-ThT measurements were acquired to study the dose-dependent effect of the OHQ derivatives on the amyloid aggregation, as previously reported for similar compounds.22 Briefly, solutions containing Aβ1–42 (15 μm), ThT (45 μm) in phosphate buffer 10 mM at pH 7.4 were supplemented with the compounds of interest, being the compound/peptide ratio between 0 and 15. The solutions were incubated at 37 °C. After 50 h under shaking, ThT fluorescence intensity (450 nm excitation, 480 nm emission) was measured in triplicate. The percent variation between the fluorescence intensity of any sample and that of the control (ThT containing solution in the presence of Aβ1–42) was plotted as a function of the compound/peptide ratio and fitted by using the four parameter logistic nonlinear regression model:
The kinetic measurements were also carried out in the absence of ThT. In this case, the amyloid aggregation was monitored by turbidimetric measurements. Positive and negative controls were used to ensure the validity of the results. Turbidity was calculated by the difference in absorbance at 405 nm between the sample and its matched control that did not contain Aβ.
Footnote |
† Electronic supplementary information (ESI) available: ThT assay. See DOI: 10.1039/c6ra04204j |
This journal is © The Royal Society of Chemistry 2016 |